Prot# CC-10004-PSOR-009: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis

Project: Research project

StatusFinished
Effective start/end date7/14/117/14/17

Funding

  • INC Research, LLC (CC-10004-PSOR-009)
  • Celgene Corporation (CC-10004-PSOR-009)